04:05:52 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



News for U:ACST from 2023-05-07 to 2024-05-06 - 17 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-02-12 08:00U:ACSTNews ReleaseAcasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
2024-02-01 08:00U:ACSTNews ReleaseAcasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
2023-12-13 08:00U:ACSTNews ReleaseAcasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
2023-11-13 08:00U:ACSTNews ReleaseAcasti Announces Second Quarter 2024 Financial Results and Business Highlights
2023-10-23 08:00U:ACSTNews ReleaseAcasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
2023-10-04 08:00U:ACSTNews ReleaseAcasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)
2023-09-26 08:00U:ACSTNews ReleaseAcasti Announces $7.5 Million Private Placement Equity Financing
2023-09-06 08:00U:ACSTNews ReleaseAcasti to Participate in the H.C. Wainwright Global Investment Conference
2023-08-11 07:00U:ACSTNews ReleaseAcasti Announces First Quarter 2024 Financial Results and Business Highlights
2023-08-09 16:05U:ACSTNews ReleaseAcasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting
2023-07-10 09:00U:ACSTNews ReleaseAcasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients
2023-07-07 08:00U:ACSTNews ReleaseAcasti Pharma Announces 1-for-6 Reverse Stock Split
2023-07-05 09:00U:ACSTNews ReleaseAcasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023
2023-06-23 07:00U:ACSTNews ReleaseAcasti Pharma Reports Fiscal Year 2023 Operational Results
2023-06-22 09:00U:ACSTNews ReleaseAcasti Announces Appointment of New Scientific Advisory Board Members
2023-05-17 09:00U:ACSTNews ReleaseAcasti to Participate in the Lytham Partners Spring 2023 Investor Conference
2023-05-08 07:00U:ACSTNews ReleaseAcasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025